Novo Nordisk and Eli Lilly sued over claims GLP-1 drugs caused vision loss and eye damage
This is an editorial summary of research originally reported by BMJ News. ProductSafer does not claim ownership of the underlying research. All intellectual property belongs to the original publishers.
Dozens of people allege that semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide caused eye damage and are suing the makers. The claims are unproven and patients should not stop treatment without medical advice.
Dozens of people are suing Eli Lilly and Novo Nordisk, the makers of GLP-1 medications. They say the drugs caused eye damage and vision loss. These are claims in lawsuits. The excerpt does not say a court or regulator has found that the drugs cause eye harm.
The excerpt names semaglutide and tirzepatide as among the most widely used drugs to treat type 2 diabetes and promote weight loss. It says Novo Nordisk markets semaglutide as Ozempic, Wegovy and Rybelsus. The excerpt cuts off while describing tirzepatide. Read the full notice at the source link.
What you can do: the excerpt gives no advice for patients. If you feel unwell, contact a doctor or NHS 111.
What you can doAI-generated
- ✓Talk to your eye doctor before starting semaglutide or tirzepatide and mention you're taking a GLP-1 drug at every visit.
- ✓Ask your prescribing doctor specifically whether the vision loss claims match your personal risk factors, since the lawsuits are unproven and most patients haven't reported problems.
- ✓Watch for blurred vision, floaters, or sudden vision changes while on Ozempic, Wegovy, Rybelsus, or tirzepatide and report them to your doctor right away.
- ✓Stop taking the drug only if your doctor tells you to, not because of the lawsuits. Vision loss linked to these medications hasn't been proven in court or confirmed by regulators.
Always consult a healthcare professional for personal medical advice.
Read the full report at the original source
BMJ NewsWas this finding useful?
Community discussion
Join the discussion
Comments are reviewed before appearing publicly.